Meet Our Team
When Steve & Gert joined forces back in 2013, they shared a vision to bring a new level of analytical capability to computational biology and healthcare, building on over 20 years’ experience each in delivering new technologies and products to enable the discovery of richer and more useful links between disease and risk.
Never afraid to innovate, Steve has over 25 years’ experience building teams to develop and commercialize ground breaking data science and informatics applications in life science and healthcare. He has gained experience working at senior levels in the UK, EU and US for Fortune 500 and start-up companies. Steve is a former Global Director of Research Informatics for Astra A/B and has consulted with drug discovery and safety teams in over 20 biopharma companies. He was CEO of Synomics Ltd and led teams in Oxford Molecular, Viaken, BioWisdom and Cresset Biomolecular, supplying innovative drug discovery tools. He was involved in Oxford Molecular’s IPO and acquisition of 11 international businesses. Steve has raised significant venture and
non-dilutive funding for multiple businesses in the US and UK. He is an Advisory Council member for Breast Cancer Now and UKCRC.
Gert is an entrepreneur with over 20 years of experience of driving new innovations in AI, precision medicine and digital health by combining novel but proven software technologies. He is the principal inventor on our patents for the RACE technologies and has won a number of major awards for his innovations. He began applying RACE in 1996 across a range of industry specific and safety critical applications including product configuration (CPQ), nuclear power plant design, consumer electronics and railroad planning system. Via collaborators and scientists, engineers and commercial experts, Gert has also helped solve challenges in clinical genomics and bioinformatics including how to efficiently conduct whole genome studies based on multiple combinations of SNPs or other markers.
Veronique has over 30 years’ international experience in healthcare, gained across a broad range of functions and industry sectors. She is a former director of corporate strategy and head of venture strategy at AstraZeneca, where she was responsible for global corporate venturing activities, including the creation and $40M financing of the company’s first spinout, Albireo Pharma. She has also held posts in clinical research, licensing, M&A, venture capital and the NHS. This varied experience has given her an in- depth understanding of what is required to translate cutting edge science into commercial reality. Veronique is a non-executive director of International Biotechnology Trust plc. and of the Stevenage Bioscience Catalyst. She is a member of the Scientific Committee of Breast Cancer Now, and of the Council and Finance and Investment Committee of Queen Mary University London.
Serdar is a seasoned technology executive with a diverse background in medicine, biomedical engineering, computer science, and artificial intelligence. He has worked with the best and brightest in large aerospace companies to start-ups, and from premier corporate labs to outstanding government R&D organizations. His career has taken him to the West Coast (Silicon Valley) and East Coast (Cambridge, MA) of the US as well as recent international consulting roles in the UK, Israel, and Japan. Serdar is passionate about making a lasting impact on people’s lives by helping understand and manage complex diseases. He brings his vast experience and expertise in a wide variety of disciplines together with a deep network of professional connections to solve all of RowAnalytics’ operational problems.
Marcin has been involved in the core development of most of the RowAnalytics’ technologies. He has hands-on expertise of the design, development and deployment of a multitude of technologies, ranging from trading systems, bioinformatics and data science. Marcin is extremely well connected to Polish and European bioinformatics and data science communities. Following graduation from the University of Warsaw, his PhD focused on applying AI methods in structural bioinformatics. During his postdoctoral research at Mathematical Medicine, Nationwide Children’s Hospital, Columbus, OH, Marcin worked on multiple projects that combined next generation sequencing, statistics, bioinformatics and biomedical research. Marcin is passionate about bringing his experience and expertise to the delivery of precision medicine.
Arvind is a scientist who crossed over to the business side of the healthcare industry and has in depth understanding of early drug discovery and what biotech companies need to do to commercialise their scientific research. Arvind has an international background from the UK, the Nordics and US and extensive experience gained in both the Biotechnology and Pharmaceutical sectors across multiple therapy areas. She has large pharma research and business development experience from Roche and AstraZeneca, where she was involved in spinning out Albireo Pharma. As CBO for a number of biotech companies, she has been involved in the IPO of the Danish Biotech company Zealand Pharma and the acquisition of Ziarco, a Pfizer UK spinout, by Novartis. Arvind has also closed a number of in and out licensing deals, raised investments and secured grants for emerging start-ups in the UK and Denmark.
More about Steve
Steve is a serial technology entrepreneur and occasional angel investor specializing in informatics with a strong track record of building world-class companies, teams and products mainly for the life science industry. He has been directly involved in raising over £50M venture funding for various businesses. Steve has designed, built and brought to market a number of innovative and commercially successful products to support drug discovery and clinical informatics.
Steve has a broad range of technical, senior management, commercial and corporate skills and experience, which I have gained at senior levels in start-up, emerging and Global Fortune 500 companies. He has participated in an London Stock Exchange main market flotation and 11 corporate acquisitions.
Steve has consulted widely for a variety of top 100 life science companies on informatics, business and scientific projects and gained extensive international experience having worked in UK, Europe and the USA. He has published over 30 papers and principal inventor on 24 patents & applications.
- Applications of large scale ontology and semantic technologies (including semantic web) to business problems.
- Semantic integration of structured and unstructured (free text) data.
- Commercialization and marketing strategies for innovative high-tech products and services.
- Translational and stratified medicines research.
- Strong life sciences background specializing in protein structure modelling and computational chemistry, with extensive knowledge of a variety of drug discovery and development technologies.
More about Veronique
Veronique has held a variety of senior international roles in the healthcare industry across several therapeutic areas and functions, including drug development, medical marketing, business development and M&A at AstraZeneca and Grünenthal GmbH. She has also worked in venture capital, as an investment manager with the Rothschild Bioscience Unit in London, and spent five years as a clinician in teaching hospitals in London.
She is a non-executive director of Stevenage Bioscience Catalyst, and Senior Independent Director of International Biotechnology Trust plc. She is a member of the Scientific Committee of Breast Cancer Now, and the Council and Finance and Investment Committee of Queen Mary, University of London. She sits on the advisory board of QMUL School of Business and Management business and the QMUL Life Sciences in Whitechapel initiative.
Veronique holds a medical degree from St Bartholomew’s Hospital Medical School, a BSc in Psychology from University College London and an MBA from INSEAD. She has been awarded the Institute of Directors’ Diploma in Company Direction (Distinction).
More about Gert
Gert is a pioneer in the development of Array Based Logic approaches and systems. His inventions enable the identification of combinations of factors in very complex data spaces that influence an outcome, several orders of magnitude quicker and with higher confidence than existing statistical and machine learning methods.
Gert has applied Array Based technologies at various scales from embedded logic controllers in audio-visual systems, advanced and comprehensive product configuration (CPQ) in complex manufacturing through to projects replacing 1,000 node supercomputers with single GPU devices, e.g. in performing multi-SNP GWAS studies to identify novel clusters of multiple disease associated biomarkers.